Top

Annals of Hematology

Published in:

01-08-2017 | Letter to the Editor

Co-mutated CALR and MPL driver genes in a patient with myeloproliferative neoplasm

Authors: Mónica Bernal, Pilar Jiménez, Jose Puerta, Francisco Ruíz-Cabello, Manuel Jurado

Published in: Annals of Hematology | Issue 8/2017

Excerpt

Dear Editor, …

Levine RL, Wadleigh M, Cools J et al (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7(4):387–397CrossRefPubMed

Klampfl T, Gisslinger H, Harutyunyan AS et al (2013) Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 369(25):2379–2390. doi:10.1056/NEJMoa1311347 CrossRefPubMed

Pikman Y, Lee BH, Mercher T et al (2006) MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 3(7):e270CrossRefPubMedPubMedCentral

Kralovics R, Passamonti F, Buser AS et al (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352(17):1779–1790CrossRefPubMed

Defour JP, Chachoua I, Pecquet C et al (2016) Oncogenic activation of MPL/thrombopoietin receptor by 17 mutations at W515: implications for myeloproliferative neoplasms. Leukemia 30:1214–1216PubMed

Chachoua I, Pecquet C, El-Khoury M et al (2016) Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants. Blood 127:1325–1335CrossRefPubMed

Nangalia J, Massie CE, Baxter EJ et al (2013) Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med 369(25):2391–2405CrossRefPubMedPubMedCentral

Tefferi A, Pardanani A (2014) Genetics: CALR mutations and a new diagnostic algorithm for MPN. Nat Rev Clin Oncol 11(3):125–126. doi:10.1038/nrclinonc.2014.16 CrossRefPubMed

Tefferi A, Lasho TL, Finke CM et al (2014) CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons. Leukemia 28(7):1472–1477. doi:10.1038/leu.2014.3 CrossRefPubMed

10.

Usseglio F, Beaufils N, Calleja A et al (2017) Detection of CALR and MPL mutations in low allelic burden JAK2 V617F essential thrombocythemia. J Mol Diagn 19(1):92–98. doi:10.1016/j.jmoldx.2016.08.006 CrossRefPubMed

Title: Co-mutated CALR and MPL driver genes in a patient with myeloproliferative neoplasm
Authors: Mónica Bernal
Pilar Jiménez
Jose Puerta
Francisco Ruíz-Cabello
Manuel Jurado
Publication date: 01-08-2017
Publisher: Springer Berlin Heidelberg
Published in: Annals of Hematology / Issue 8/2017
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-017-3023-9

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Co-mutated CALR and MPL driver genes in a patient with myeloproliferative neoplasm

Excerpt

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 8/2017

Assessment of the circulating cell-free DNA marker association with diagnosis and prognostic prediction in patients with lymphoma: a single-center experience

Influence of TNF and IL6 gene polymorphisms on the severity of cytopenias in Argentine patients with myelodysplastic syndromes

Vitamin D and plasma cell dyscrasias: reviewing the significance

Erratum to: Good adherence to imatinib therapy among patients with chronic myeloid leukemia—a single-center observational study

Autologous stem cell transplantation (ASCT) in patients with mantle cell lymphoma: a retrospective study of the Spanish lymphoma group (GELTAMO)

Variant of classical high grade PTLD: post-transplant EBV-negative T cell lymphoblastic leukaemia after solid organ transplantation

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page